India's diabetes treatment is expected to shift towards GLP-1 medications, offering significant benefits in glucose control, weight management, and protection for heart and kidney health. These drugs, including semaglutide and tirzepatide, are projected to lead the anti-diabetes market, potentially phasing out older treatments. The anti-obesity drug market has also seen mainstream acceptance, with injectables like Mounjaro and Wegovy driving substantial growth in the currently 22,280 crore Indian diabetes market.